DE69534702D1 - Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen - Google Patents

Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen

Info

Publication number
DE69534702D1
DE69534702D1 DE69534702T DE69534702T DE69534702D1 DE 69534702 D1 DE69534702 D1 DE 69534702D1 DE 69534702 T DE69534702 T DE 69534702T DE 69534702 T DE69534702 T DE 69534702T DE 69534702 D1 DE69534702 D1 DE 69534702D1
Authority
DE
Germany
Prior art keywords
molecules
expression
increasing
mhc class
endogenous peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534702T
Other languages
English (en)
Other versions
DE69534702T2 (de
Inventor
A Jefferies
Reinhard Gabathuler
S Reid
Gerassimos Kolaitis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of DE69534702D1 publication Critical patent/DE69534702D1/de
Application granted granted Critical
Publication of DE69534702T2 publication Critical patent/DE69534702T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69534702T 1994-09-23 1995-09-22 Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen Expired - Lifetime DE69534702T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31144294A 1994-09-23 1994-09-23
PCT/CA1995/000544 WO1996009380A1 (en) 1994-09-23 1995-09-22 Method of enhancing expression of mhc class i molecules bearing endogenous peptides
US311442 1999-05-14

Publications (2)

Publication Number Publication Date
DE69534702D1 true DE69534702D1 (de) 2006-01-26
DE69534702T2 DE69534702T2 (de) 2006-08-24

Family

ID=23206878

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534702T Expired - Lifetime DE69534702T2 (de) 1994-09-23 1995-09-22 Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen

Country Status (5)

Country Link
US (4) US6361770B1 (de)
EP (1) EP0783573B1 (de)
JP (1) JP4418965B2 (de)
DE (1) DE69534702T2 (de)
WO (1) WO1996009380A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4418965B2 (ja) 1994-09-23 2010-02-24 タップイミューン・インコーポレイテッド 内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法
WO1996034952A1 (de) * 1995-05-04 1996-11-07 Boehringer Ingelheim International Gmbh Expression von tap und lmp in tumorzellen
US5792604A (en) * 1996-03-12 1998-08-11 University Of British Columbia Method of identifying MHC-class I restricted antigens endogenously processed by cellular secretory pathway
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
EP1838330A4 (de) * 2004-12-13 2010-07-07 Peplin Research Pty Ltd Behandlung von soliden tumoren
AU2006351377A1 (en) * 2006-11-30 2008-06-05 University Of British Columbia Poxviridae treatment comprising TAP-1 and/or TAP-2 as a molecular adjuvant
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
AU2009208735A1 (en) * 2008-01-28 2009-08-06 Tapimmune Inc. Tapasin augmentation for enhanced immune response
CN101343311B (zh) * 2008-08-26 2012-01-04 东南大学 一种多亚基蛋白的复性方法
US20100322963A1 (en) * 2009-06-18 2010-12-23 Tapimmune, Inc. Low dose inoculation with tap for anti-tumor immunity
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
MX350274B (es) 2012-05-16 2017-08-31 Immune Design Corp Vacunas para hsv-2.
US9993534B2 (en) 2013-03-12 2018-06-12 Wisconsin Alumni Research Foundation Method of treating fungal infection
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
NZ756395A (en) 2017-03-16 2024-01-26 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
ES2963638T3 (es) 2017-03-16 2024-04-01 Alpine Immune Sciences Inc Proteínas inmunomoduladoras de variantes de PD-L1 y usos de las mismas
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CA3096287A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
KR20210089146A (ko) 2018-09-19 2021-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
JP2022510276A (ja) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
CA3136816A1 (en) 2019-04-17 2020-10-22 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
WO2021226551A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4418965B2 (ja) * 1994-09-23 2010-02-24 タップイミューン・インコーポレイテッド 内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法

Also Published As

Publication number Publication date
JP4418965B2 (ja) 2010-02-24
US20100080776A1 (en) 2010-04-01
EP0783573A1 (de) 1997-07-16
EP0783573B1 (de) 2005-12-21
JPH10505755A (ja) 1998-06-09
DE69534702T2 (de) 2006-08-24
US20030082195A1 (en) 2003-05-01
US7994146B2 (en) 2011-08-09
US6361770B1 (en) 2002-03-26
US7378087B2 (en) 2008-05-27
WO1996009380A1 (en) 1996-03-28
US20120135031A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
DE69534702D1 (de) Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
DE69334108D1 (de) Elektrisches Verfahren zur Bestimmung von Molekülen
DE69535721D1 (de) Verfahren zur Verbesserung von der Löslichkeit von pflanzlichen Proteinen
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
DE69825521D1 (de) Verfahren zur Herstellung von Silicon-in-Wasser-Emulsionen
DE59408901D1 (de) Verfahren zur Herstellung von Polyacetalen
DE69532492D1 (de) Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
DE69508124D1 (de) Verfahren zur Herstellung von klaren Antiperspirantgelen
DE69502374D1 (de) Verfahren zur Herstellung von Methylcyanoacrylat
DE59804785D1 (de) Verbessertes Verfahren zur Stabilisierung von Proteinen
DE59705243D1 (de) Verfahren zur Herstellung von N-substituierten cyclischen Aminen
DE69511442D1 (de) Verfahren zur Herstellung von Polyorganosilan
DE69816622D1 (de) Verfahren zur Steigerung der Expression von Fremdproteinen
DE69500138T2 (de) Verfahren zur dauerhaften Verformung von Keratinmaterialien
DE59407859D1 (de) Verfahren zur Herstellung von N-substituierten Pyrazolen
DE69831718D1 (de) Verfahren zur Herstellung von N-Alkylimidazolen
DE59402263D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolid-2-onen
DE59706033D1 (de) Verfahren zur qualitativen Beurteilung von bearbeitetem Material
DE59301661D1 (de) Verfahren zur Herstellung von N-acylierten p-Aminophenolen
DE69509157T2 (de) Verfahren zur Dauerhaften Verformung von Keratinsubstanzen
DE69707230D1 (de) Verfahren zur Herstellung von 2-Dimethylnaphthalen
DE69304224D1 (de) Verfahren zur Herstellung von P-Aminophenolen
DE69722724D1 (de) Verfahren zur Herstellung von N-substituierten Laktamen
DE69805744D1 (de) Verfahren zur Herstellung von alpha-Aminonitrilen und alpha-Aminosäuren
DE69816944D1 (de) Verfahren zur Herstellung von einem aliphatischen Aminderivat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition